Skip to Content
Merck
  • Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1.

Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2005-12-16)
Sonia Rodríguez Nóvoa, Pablo Barreiro, Ana Rendón, Ana Barrios, Angélica Corral, Inmaculada Jiménez-Nacher, Juan González-Lahoz, Vincent Soriano
PMID16355344
ABSTRACT

The 3435C-->T polymorphism at the multidrug resistance gene 1 (MDR1) was examined in 74 patients with human immunodeficiency virus who initiated atazanavir therapy. The MDR1 genotype distribution at position 3435 was 28% CC, 45% CT, and 27% TT. Plasma levels of atazanavir were significantly higher in patients with genotype CC than in those with CT or TT, and bilirubin levels correlated with atazanavir concentrations.